AddedRisk Factors
If we fail to develop or maintain an effective system of internal controls, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial reporting, which would harm our business and the trading price of our common stock.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedRisk Factors
Effective internal controls are necessary for us to provide reliable financial reports, prevent fraud and operate successfully as a public company. If we cannot provide reliable financial reports or prevent fraud, our reputation and operating results would be harmed. We cannot be certain that our efforts to develop and maintain an effective system of internal controls will be successful, that we will be able to maintain adequate controls over our financial processes and reporting in the future, or that we will be able to comply with our obligations under Section 404 of the Sarbanes-Oxley Act of 2002. Any failure to develop or maintain effective internal controls, or difficulties encountered in implementing or improving internal controls, could harm our operating results or cause us to fail to meet our reporting obligations. Ineffective internal controls could also cause investors to lose confidence in our reported financial information, which would likely have a negative effect on the trading price of our common stock.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RemovedRisk Factors
•failure to integrate successfully the businesses of Quidel and Ortho in the expected timeframe;
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
a small number of contract manufacturers and a large number of single and sole source suppliers makes us vulnerable to possible production capacity or other constraints of such suppliers or in their supply chain and reduced control over manufacturing, product availability, delivery schedules and costs.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
Our collaboration arrangements may not operate according to our business strategy if our collaboration arrangement partners fail to fulfill their obligations.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
We may engage in acquisitions or divestitures or discontinue business operations, and may encounter difficulties integrating acquired businesses with, or disposing of divested or discontinued businesses from, our current operations; therefore, we may not realize the anticipated benefits of these acquisitions, divestitures or discontinuances.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
The occurrence of any of these or other factors over which we do not have control could lead to reduced revenue and profitability.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
The failure to integrate successfully the businesses of Quidel and Ortho would adversely affect our future business and financial performance.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
As a result of the Combinations, we have been and continue to devote significant management and employee attention and resources to integrate the business practices and operations of Quidel and Ortho. The integration process may disrupt our business and, if implemented ineffectively, could preclude realization of the full benefits we expect to result from the Combinations. Any failure to meet the challenges involved in successfully integrating the operations of Quidel and Ortho or otherwise to realize the anticipated benefits of the Combinations could also seriously harm our results of operations. In addition, the integration of Quidel and Ortho may result in material unanticipated problems, expenses and liabilities. The difficulties of combining the operations of Quidel and Ortho, some of which we have already experienced, include, among others:
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
•managing a significantly larger company and expanded business operations and the associated increased costs and complexity;
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
•the possibility of faulty assumptions underlying expectations regarding the integration process and results;
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
•integrating IT, enterprise resource planning (“ERP”), customer relationship management and other systems, including the implementation of a new ERP system to integrate certain existing business, operational and financial processes,
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
which requires significant investment of capital and human resources and the reengineering of many business processes;
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
•managing tax costs or inefficiencies associated with integrating the operations of Quidel and Ortho; and
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RewordedRisk Factors
While we endeavor to have a strong culture of compliance and an adequate system of internal controls, including procedures to minimize and detect fraud in a timely manner, as well as processes for complying with OFAC authorizations or exemptions, there can be no assurance that our policies and procedures will may not be followed at all times or will effectively detect and prevent violations of applicable laws by one or more of our employees, consultants, agents or partners or other intermediaries working on our behalf and, as a result, we could be subject to penalties criminal, civil and administrative penalties, including prohibitions on the conduct of our business in certain jurisdictions, debarment or exclusion from federal healthcare or global tender programs, and other material adverse consequences on our business, financial condition or results of operations.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
Like any large corporation, from time to time the information systems on which we rely, including those controlled controlled, developed and managed by third parties, are subject to computer viruses, malicious software, attacks by hackers hackers, ransomware, supply-chain compromises, credential theft and attacks targeting our enterprise and manufacturing environments, product vulnerabilities, security breaches and other forms of cyber intrusions or unauthorized access, any of which can create system disruptions, shutdowns or unauthorized disclosure of personal or confidential information, all of which can take time and be timely and costly to remediate. remediate, affect our ability to sell the affected product or service, and expose us to damages.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our international operations are subject to inherent macroeconomic, geopolitical and regulatory risks, risks and a range of diverse regulatory requirements, the occurrence of which, including those over which we have no control, or failure to comply with these regulatory requirements, could adversely impact our financial performance, cause interruptions in our or suspensions of applicable international business operations, impede our international growth and operations, cause reputational harm, and subject us to civil or criminal fines and penalties, other remedial measures and legal expenses.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
As a result, if Fluctuations or declines in the sales or revenues of our respiratory products fluctuate or decline for any reason, products, whether as a result of a mild respiratory season, market share loss or price pressure, obsolescence, regulatory matters, matters or any other reason, our operating results would be could materially and adversely affected on a disproportionate basis. affect our operating results.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
If we elect not Our decisions regarding, or ability to or are unable to satisfy satisfy, such evolving standards for identifying, measuring and reporting sustainability metrics, including sustainability-related disclosures that may be required of public companies by regulators, stakeholders may conclude that not satisfy all of our performance related to corporate responsibility and sustainability matters is inadequate. stakeholders.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our Credit Agreement governs our senior secured credit facilities, which consist of (i) a $1.15 billion Term Loan in an original amount of $2,750.0 A, (ii) a $100.0 million DDTL Term Loan A, (iii) a $1.45 billion Term Loan B and (ii) an $800.0 (iv) a $700.0 million Revolving Credit Facility.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
However, We have entered into a series of interest rate swap agreements to hedge our interest rate exposures related to our variable rate borrowings under the credit facilities; however, it is possible that these hedging instruments or any future hedging instruments we enter into may not fully or effectively mitigate our interest rate risk and we may decide not to maintain hedging instruments in the future.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
While we proactively work with our suppliers, manufacturers, distributors, industry partners and government agencies to address these challenges in our efforts to meet the needs of our customers, such disruptions and challenges have materially affected and could further materially affect our ability to timely manufacture and distribute our products and have unfavorably impacted and could further unfavorably impact our results of operations.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, in some cases, we may sell products or provide services that are reliant on the use or commercial availability of third-party products, including medical devices or equipment, and regulatory restrictions placed upon any such third-party products could have a material adverse impact on the sales or commercial viability of our related products or services.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
The Credit Agreement contains a number of restrictive covenants that impose significant operating and financial restrictions on us and may limit our ability to engage in acts that may be in our long-term best interest, including restrictions including, among other matters, limitations on our ability, asset sales, mergers, indebtedness, liens, investments and the ability of our subsidiaries, to: transactions with affiliates.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
We are highly dependent on IT networks and systems, including our office networks, operational environment, special purpose networks, systems and software used in or to provide our products and services, including operating our instruments instruments, automation systems and other devices, whether internally developed or by third parties and collaboration partners, and those networks and systems managed by vendors or third parties, including cloud/SaaS platforms supporting connected instruments, to securely collect, process, transmit, disclose, share, use and store electronic information (including sensitive personal information and proprietary or confidential information) (collectively, “information systems”).
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
Disruptions at the FDA and other government agencies, including disruptions caused by funding shortages or statutory, regulatory or policy changes, could hinder their ability to hire, retain or deploy key leadership and other personnel, prevent them from performing normal business functions on which the operation of our business may rely, or otherwise prevent new or modified products from being developed, cleared, approved or commercialized in a timely manner or at all, which could negatively impact our business.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
This If available, this would increase our capital and other costs, which could adversely affect our earnings and cash resources.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
In addition, due to regulatory requirements relating to the qualification of suppliers, we may not be able to establish additional or replacement sources on a timely basis or without excessive substantial cost.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
For example, stringent requirements of the FDA and other regulatory authorities regarding the manufacture of certain of our products may prevent us from quickly establishing additional or replacement sources for the raw materials, products, components or manufacturing services that we use, or from doing so without excessive substantial cost.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Since we may do not exercise exclusive control over our current or future collaboration arrangements, we may not be able to require our collaboration arrangement partners to take actions that we believe are necessary to implement our business strategy.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
The revised reimbursement methodology under PAMA generally results in relatively lower reimbursement under Medicare for clinical diagnostic lab tests than has been historically available.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
We also maintain insurance coverage for cybersecurity incidents, which although it may not be adequate or cover all incidents.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
As the UPC is a new court system, there is no limited precedent for the court, increasing the uncertainty of any litigation.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
If we cannot retain these agreements or arrangements, we may not be able to sell, develop or commercialize certain of our products.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
We may encounter challenges entering into contracts with government entities due to government-sponsored tendering requirements, and any contracts that we have entered into or will enter into with government entities may involve future funding, compliance and possible sanctions penalties risks.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
We will be are exposed to significant risks in relation to compliance with anti-bribery and anti-corruption laws and regulations and economic sanctions programs.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
As a result of our indebtedness, a portion of our cash flows will be are required to pay interest and principal on our outstanding indebtedness, and we may not generate sufficient cash flows from operations, or have future borrowings available under the Revolving Credit Facility, to enable us to repay our indebtedness or to fund our other liquidity needs.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Our success will depend depends in part upon our ability to attract, motivate and retain executives and sales, marketing, manufacturing, technical, scientific, technology and other key personnel.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
In the second quarter of 2025, we launched multi-year, enterprise-wide cost-reduction, strategic productivity and margin improvement initiatives (the “Optimization Plan”) that aim to (i) realign our costs with our long-term revenue expectations, (ii) drive operational efficiencies in manufacturing and distribution cost bases and (iii) support and align with our strategy to invest in key priorities. The cumulative pre-tax charges to be incurred by us to implement the Optimization Plan are expected to be approximately $100 million through 2027. The Optimization Plan is expected to deliver net cost savings of approximately $50 million to be achieved through 2027. The key initiatives of the Optimization Plan are:
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
•Rationalization and consolidation of facilities to reduce operational costs, improve processes, and optimize resource allocation;
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
•A structured approach to procurement to drive identified sourcing cost savings; and
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
•A distribution rationalization plan, mainly in EMEA, to streamline a complex corporate structure to reduce costs and improve efficiency.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
We continue to monitor our operations for cost-reduction, strategic productivity and margin improvement opportunities to streamline our operations globally and identify additional cost savings. We may expand our cost-reduction, strategic productivity and margin improvement initiatives in the future, the costs of which could be material.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
Additionally, in the second quarter of 2025, we announced a strategic refocusing of our Molecular Diagnostics business, including our plan to discontinue the development of the SAVANNA platform, which exit we expect to be substantially complete by the first half of 2027, and our intent to acquire LEX Diagnostics.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
In April 2025, the U.S. announced tariffs on imports from most countries, including significant tariffs on imports from the U.K., Canada, Mexico and China, leading to increasing trade and political tensions. In response to tariffs, other countries have implemented retaliatory tariffs on U.S. goods. In addition, the U.S. has announced potential new tariffs and related tariff actions affecting companies in the pharmaceutical and biotechnology industries, including a Section 232 national security investigation of imports of personal protective equipment, medical consumables, and medical equipment, including devices. These actions and the related rising political tensions could negatively impact global macroeconomic conditions and the stability of global financial markets. Currently, as a result of recently effected tariffs, we are incurring incremental costs of parts and materials that we use to produce products, as well as incremental costs to ship finished goods to customers. Although the Company plans to, and we have thus far, substantially offset such incremental costs through operating measures, including supply chain adjustments, current and future tariffs could have a material adverse effect on our business, financial condition and results of operations, including through increased supply chain costs. While trade negotiations are ongoing and certain bilateral trade deals have been announced, there remains substantial uncertainty about the duration of existing tariffs, tariff levels, implementation of announced tariffs or imposition of additional tariffs, the potential implications of the Section 232 investigations, litigation challenging tariffs and whether additional tariffs or retaliatory actions may be imposed, modified or suspended. We continue to closely monitor these events as they unfold and assess their potential impact on our operations to inform our response strategy.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
A recent research report was issued regarding the potential for the adoption of a dry chemistry VBP program in the Jiangxi province of China. At this time, we have no indication that such a program will be implemented or if our products would be included in such a program. Should this occur, we would seek to implement remediation efforts to offset potential costs. Based on current information, we believe that any potential business impact would likely be insignificant to our total annualized revenue.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
(1) Certain reclassifications have been made to prior period amounts to conform to the current period presentation.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
On July 4, 2025, the OBBBA was enacted in the U.S. The OBBBA includes significant provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. Our results for the fiscal year ended 2025 include the impacts of OBBBA on our Consolidated Financial Statements.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
On August 21, 2025, we entered into the Credit Agreement by and among us, as borrower, Bank of America, and the other lenders and L/C issuers party thereto. Pursuant to the Credit Agreement, the Lenders provided us with (i) a $1.15 billion Term Loan A, (ii) a $100.0 million DDTL Term Loan A, (iii) a $1.45 billion Term Loan B and (iv) a $700.0 million Revolving Credit Facility. The Financing is guaranteed by certain of our material domestic subsidiaries and is secured by liens on substantially all of our assets and the Guarantors’ assets, excluding real property and certain other types of excluded assets. Loans under the Credit Agreement will bear interest at a rate equal to the Term SOFR, plus the Applicable Rate, or Base Rate, plus the Applicable Rate (each as defined in the Credit Agreement). On the Closing Date, we borrowed the entire amount of the Term Loan A and the Term Loan B, and the effective interest rates as of December 28, 2025 were 6.87% and 8.43%, respectively.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
We used the proceeds of the Term Loan A and the Term Loan B, along with its cash on hand, to (i) repay the remaining $2.21 billion and $490.0 million owed under the previous term loan and previous revolving credit facility, respectively, under the Prior Credit Agreement, which was terminated upon such repayment, including principal, accrued interest and outstanding fees and (ii) pay the fees and expenses incurred in connection with the Financing.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RemovedMD&A
On May 27, 2022, pursuant to the BCA, Quidel and Ortho consummated the Combinations and each of Quidel and Ortho became a wholly owned subsidiary of QuidelOrtho. Our Consolidated Financial Statements for fiscal years ended 2024 and 2023 each include a full year of Ortho operations. For additional information about the Combinations, refer to Part II, Item 8, “Financial Statements and Supplementary Data—Note 2. Business Combination.”
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
We obtain raw materials from reputable outside suppliers and believe our business relationships with them are good. Some of our raw materials are available from a limited number of sources. While we encountered increasing pressures on raw material pricing during fiscal years ended 2023 and 2022, inflationary impacts during fiscal year ended 2024 lessened and returned closer to pre-COVID-19 pandemic levels. To help mitigate these supply chain challenges, we (i) partner with suppliers to invest in additional capacity and raw material inventory, (ii) diversify our supply base, where possible, to minimize reliance on a single source of supply for key raw materials and components, (iii) create redundancy in our global supply chain and (iv) insource activity where it makes strategic and financial sense. In addition, we routinely evaluate our supply chain for potential gaps and continue to take other steps intended to help address continuity.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
year ended 2022 was primarily due to acquisition costs attributable to the Combinations, partially offset by higher integration-related costs.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
On August 17, 2022, our Board authorized the Stock Repurchase Program, allowing us to repurchase up to $300.0 million of our common stock, which expired on August 17, 2024. We did not repurchase any shares of our common stock during fiscal year ended 2024 through the expiration date. For the fiscal year ended 2023, we repurchased 120,000 shares of outstanding common stock under the Stock Repurchase Program for approximately $7.2 million.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
costs of $2,388.3 million, repurchases of common stock of $74.3 million and payments of $37.7 million for contingent and deferred consideration.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
•our ability to successfully integrate the Ortho business and realize cross-selling revenue synergies;
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
The estimated fair values of the EMEA and Latin America reporting units exceeded their respective carrying values and consequently did not result in an impairment. The excess of the estimated fair value over carrying value (expressed as a percentage of carrying value for the respective reporting unit) was approximately 8% and 45%, respectively. To evaluate the sensitivity of the fair value calculations used in the interim goodwill impairment test for the EMEA and Latin America reporting units, we applied a hypothetical 5% decrease to the fair value of each reporting unit and compared that hypothetical value to the reporting unit’s carrying value. Based on this hypothetical 5% decrease, the excess of the estimated fair value over carrying value (expressed as a percentage of carrying value for the respective reporting unit) was approximately 3% and 37% for the EMEA and Latin America reporting units, respectively.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
Under the acquisition method of accounting, the cost of an acquired business is assigned to the tangible and identifiable intangible assets acquired and liabilities assumed on the basis of the estimated fair values at the date of acquisition. We assess fair value, which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, using a variety of methods including, but not limited to, an income approach and a market approach, such as the estimation of future cash flows of the acquired business and current selling prices of similar assets. These valuations require us to make estimates and assumptions, especially with respect to intangible assets.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
Fair value of the assets acquired and liabilities assumed, including intangible assets, IPR&D, and contingent payments, are measured based on the assumptions and estimations with regards to variable factors such as the amount and timing of future cash flows for the asset or liability being measured, appropriate risk-adjusted discount rates, nonperformance risk, or other factors that market participants would consider. Upon acquisition, we determine the estimated economic lives of the acquired intangible assets for amortization purposes, which are based on the underlying expected cash flows of such assets. When applicable, adjustments to inventory are based on the fair market value of inventory and are recognized into income based on the period in which the underlying inventory is sold. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that is not individually identified and separately recognized. Actual results may vary from projected results and assumptions used in the fair value assessments.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
If the initial accounting for a business combination is incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. We record these adjustments to the provisional amounts with a corresponding offset to goodwill. Any adjustments identified after the measurement period are recorded in the Consolidated Statements of (Loss) Income.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RewordedMD&A
The (i) a maximum Consolidated Leverage Ratio (as defined in the Credit Agreement contains Agreement) as of the last day of each fiscal quarter of (a) 4.50 to 1.00 for each fiscal quarter in the first three years following the Closing Date and (b) 4.25 to 1.00 for each fiscal quarter thereafter; and (ii) a minimum Consolidated Interest Coverage Ratio (as defined in the Credit Agreement) of 3.00 to 1.00 as of the end of any fiscal quarter for the most recently completed four fiscal quarters.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
The decrease in Other expense, net in fiscal year ended 2024 2025 compared to fiscal year ended 2023 2024 was primarily related to (i) a prior year release of tax reserves upon the settlement of certain U.S. federal tax matters, with an offsetting benefit recorded to income tax expense, and (ii) Prior Credit Agreement amendment fees, fees in the prior year, partially offset by loss on investments in the prior year period. net foreign currency losses.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
Cash provided by operating activities was $83.0 $105.2 million for fiscal year ended 2024, 2025, and reflected a net loss of $2,052.0 $1,131.8 million and non-cash adjustments of $2,293.7 $1,362.8 million, primarily associated with a goodwill impairment charge and change in deferred tax assets and liabilities, as well as charge, depreciation and amortization, asset impairment charge write off related to restructuring, integration and other charges, and stock-based compensation expense. expense, partially offset by $148.3 million and $117.5 million in cash outflows for inventories and accounts receivable, respectively.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
Fiscal Year Ended (Dollars in millions) 2025 % of 2024 % of 2023 % of 2022 % of Total Revenues Total Revenues Total Revenues Selling, marketing and administrative $ 746.3 27.3% $ 766.8 27.6% $ 763.2 25.5% $ 621.0 19.0% Research and development 186.2 6.8% 218.7 7.9% 245.0 8.2% 187.9 5.8% Amortization of intangible assets 189.2 6.9% 203.4 7.3% 204.8 6.8% 132.5 4.1% Acquisition Restructuring, integration and integration costs other charges 263.6 9.7% 127.2 4.6% 113.4 3.8% 136.0 4.2% Goodwill impairment charge 700.7 N/M 1,822.6 N/M — N/M — N/M Asset impairment charge 9.7 N/M 56.9 N/M 4.5 N/M 2.8 N/M Other operating expenses 97.7 3.6% 51.8 1.9% 27.1 0.9% 12.3 0.4%
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
For fiscal years ended 2024 2025 and 2023, 2024, we recognized income tax benefits expense of $24.1 million in relation to loss before taxes of $1,107.7 million and an income tax benefit of $79.5 million in relation to loss before taxes of $2,131.5 million and $19.0 million in relation to loss before taxes of $29.1 million, resulting in effective tax rates of 3.7% (2.2)% and 65.3%, 3.7%, respectively.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
(Dollars in millions) December 28, December 29, December 31, 2025 2024 2023 Cash and cash equivalents $169.8 $98.3 $118.9 Marketable securities, current — 48.4 Marketable securities, non-current — 7.4 Total cash, cash equivalents and marketable securities $98.3 $174.7 Amount available to borrow under the Revolving Credit Facility $596.6 $589.0 $787.1 Working capital including cash and cash equivalents and marketable securities, equivalents, current $481.2 $220.1 $476.7
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
The decrease was primarily driven by lower demand for QuickVue decreases in sales of QUICKVUE and Sofia SOFIA SARS Antigen assays, assays and the wind-down of the U.S. donor screening business, partially offset by incremental revenues of $433.8 million from the Combinations. an increase in Labs revenues.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
Selling, marketing and administrative expenses for fiscal year ended 2024 increased 2025 decreased by $3.6 $20.5 million, or 0.5%, 2.7%, to $766.8 $746.3 million from $763.2 $766.8 million for the prior year, primarily due to higher incentive-based employee compensation costs, partially offset by lower costs of outside services and lower compensation costs related to cost-savings initiatives and lower advertising costs. actioned in 2024.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
Cash provided by financing activities was $48.8 $155.8 million for fiscal year ended 2024, 2025, and was primarily related to net proceeds from the Revolving Credit Facility long-term borrowings, net of $198.0 discount and debt issuance costs of $2,559.3 million, partially offset by payments on long-term borrowings of $143.0 $2,289.2 million and net payments from the Revolving Credit Facility of $118.0 million.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
As a result, we recorded a non-cash goodwill impairment charges charge of $17.3 $614.8 million, $68.1 million and $61.4 $17.8 million in the fourth third quarter of 2024 2025 for the EMEA, China and JPAC Latin America reporting units, respectively. respectively, which represented a full impairment of the goodwill allocated to these reporting units.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
Cost of sales, excluding amortization of intangible assets, was $1,456.0 million, or 53.3% of Total revenues, for fiscal year ended 2025, compared to $1,496.4 million, or 53.8% of Total revenues, for fiscal year ended 2024, compared to $1,500.7 million, or 50.1% of Total revenues, for fiscal year ended 2023. 2024.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
The increase decrease in cost of sales, excluding amortization of intangible assets as a percentage of revenue, was driven primarily by product mix, partially offset by a prior year period COVID-19 government award, along with the corresponding inventory reserve release of $39 million. procurement-related cost-savings initiatives actioned in 2024.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new